DAIC Articles

Nov 3, 2017 | DAIC Articles
Most Popular Cardiac Technology Content in October 2017 on DAIC

“Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC) magazine website from the month of October, based on website analytics of the month’s 163,117 pageviews:”

Nov 3, 2017 | DAIC Articles
Biotronik Orsiro DES Shows Low Five-Year Event Rates

“Biotronik’s Orsiro drug-eluting stent (DES) demonstrated high long-term safety and clinical performance according to 60-month follow-up data presented during the 2017 Transcatheter Cardiovascular Therapeutics Annual Conference (TCT 2017), Oct. 29-Nov. 2 in Denver.”

Nov 2, 2017 | DAIC Articles
Study Examines Use of CrossBoss Catheter for Chronic Total Occlusion PCI

“Crossing the occlusion with a guidewire is often the most challenging part of chronic total occlusion (CTO) percutaneous coronary intervention (PCI), and there is debate about the optimal initial crossing strategy during the procedure.”

Nov 2, 2017 | DAIC Articles
Drug-eluting Balloon is Noninferior to Drug-eluting Stent in Patients With In-stent Restenosis

“The treatment of in-stent restenosis (ISR) remains challenging in clinical practice. The DARE (Drug-eluting bAlloon for in-stent Restenosis) multicenter, randomized clinical trial evaluated the performance of the B. Braun Sequent Please drug-eluting balloon (DEB) vs. the Abbott Xience everolimus-eluting stent (EES) in patients with ISR.”

Nov 2, 2017 | DAIC Articles
Mixed Results in PREVAIL Trial Comparing Five-Year Data for LAA Closure Compared to Warfarin

“Five-year results from the PREVAIL Trial comparing left atrial appendage closure (LAAC) with the Boston Scientific Watchman device to warfarin in patients with nonvalvular atrial fibrillation found that the first composite co-primary endpoint of stroke, systemic embolism (SE), or cardiovascular/unexplained death did not achieve noninferiority.”

Nov 1, 2017 | DAIC Articles
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI

“Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strategy of culprit lesion-only percutaneous coronary intervention (PCI) reduces the composite of 30-day mortality and/or severe renal failure in patients with multivessel disease and cardiogenic shock complicating acute myocardial infarction.”

Nov 1, 2017 | DAIC Articles
TAVR Cost-Effective Compared With SAVR in Intermediate-Risk Aortic Stenosis Patients

“Analysis of the PARTNER 2A trial and the SAPIEN-3 Intermediate Risk registry found transcatheter aortic valve replacement (TAVR) to be highly cost-effective compared with surgical aortic valve replacement (SAVR) in intermediate surgical risk patients with aortic stenosis.”

Nov 1, 2017 | DAIC Articles
Double Kissing Crush Two-Stent Technique in Left Main Bifurcation Lesions Demonstrates Lower Target Lesion Failure Rates

“The double kissing (DK) crush two-stent technique was associated with a lower rate of target lesion failure at one year compared with provisional stenting (PS) in the treatment of true distal bifurcation lesions of the left main artery, according to a large-scale randomized trial.”

Nov 1, 2017 | DAIC Articles
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

“OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 2 in Denver. The results provide fresh insights into the optimal treatment of patients with acute coronary syndrome (ACS) using the COMBO Dual Therapy Stent.”

Oct 31, 2017 | DAIC Articles
Sapien 3 Valve Demonstrates Significant Cost Savings Over Surgery In Intermediate-Risk Patients

“Edwards Lifesciences Corp. announced new data demonstrating substantial economic advantages of the Edwards Sapien 3 transcatheter aortic heart valve for patients suffering from severe, symptomatic aortic stenosis (AS) who are at intermediate risk for open-heart surgery.”